FR2404639A1 - Chano-des:ethyl-apovincamine derivs. - Google Patents

Chano-des:ethyl-apovincamine derivs.

Info

Publication number
FR2404639A1
FR2404639A1 FR7729574A FR7729574A FR2404639A1 FR 2404639 A1 FR2404639 A1 FR 2404639A1 FR 7729574 A FR7729574 A FR 7729574A FR 7729574 A FR7729574 A FR 7729574A FR 2404639 A1 FR2404639 A1 FR 2404639A1
Authority
FR
France
Prior art keywords
apovincamine
derivs
ethyl
opt
troubles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7729574A
Other languages
French (fr)
Other versions
FR2404639B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omnium Chimique SA
Original Assignee
Omnium Chimique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnium Chimique SA filed Critical Omnium Chimique SA
Priority to FR7729574A priority Critical patent/FR2404639B1/en
Priority to US05/946,456 priority patent/US4200638A/en
Priority to GB7838281A priority patent/GB2005267B/en
Priority to ES473834A priority patent/ES473834A1/en
Priority to BE190805A priority patent/BE870887A/en
Priority to JP53119309A priority patent/JPS5831352B2/en
Priority to DE2842418A priority patent/DE2842418C2/en
Publication of FR2404639A1 publication Critical patent/FR2404639A1/en
Priority to BE0/201282A priority patent/BE884145R/en
Application granted granted Critical
Publication of FR2404639B1 publication Critical patent/FR2404639B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Chando-desethyl-apovincamine derivs. of formula (I) and their addn.salts, as the racemate or optical isomers, are new. In the formula R is H, 1-5C opt. branched, opt. unsatd. alkyl or benzyl and Z is H, alkyl, hydroxy, acyloxy, carbamoyloxy, methoxy or halo. Cpds. where Z is H and R is methyl and ethyl are specifically claimed.- Used for the treatment of cardio-circulatory and cerebro-vascular troubles and intermediates (I) have antianoxic and psychotropic activity and are used to treat vigilance troubles behavioural problems due to cerebral vascular damagE, cerebral sclerosis, geriatric states and as sedatives for treatment of lapses due to cranial traumatism and depression. They are administered orally, rectally or parenterally in unit doses of 0.5-700 mg. Usual daily doses are 1-500 mg
FR7729574A 1977-09-30 1977-09-30 NEW INDOLIC COMPOUNDS Expired FR2404639B1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR7729574A FR2404639B1 (en) 1977-09-30 1977-09-30 NEW INDOLIC COMPOUNDS
GB7838281A GB2005267B (en) 1977-09-30 1978-09-27 Indole derivatives their preparation and pharmaceutical compositions containing them
US05/946,456 US4200638A (en) 1977-09-30 1978-09-27 Indole derivatives and therapeutically acting drugs
BE190805A BE870887A (en) 1977-09-30 1978-09-29 NEW INDOLIC COMPOUNDS
ES473834A ES473834A1 (en) 1977-09-30 1978-09-29 Indole derivatives and therapeutically acting drugs
JP53119309A JPS5831352B2 (en) 1977-09-30 1978-09-29 Novel indole derivatives, their production methods and use as medicines
DE2842418A DE2842418C2 (en) 1977-09-30 1978-09-29 Indolonaphthyridines
BE0/201282A BE884145R (en) 1977-09-30 1980-07-03 NEW INDOLIC COMPOUNDS

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR7729574A FR2404639B1 (en) 1977-09-30 1977-09-30 NEW INDOLIC COMPOUNDS
BE0/201282A BE884145R (en) 1977-09-30 1980-07-03 NEW INDOLIC COMPOUNDS
BE884145 1980-07-03

Publications (2)

Publication Number Publication Date
FR2404639A1 true FR2404639A1 (en) 1979-04-27
FR2404639B1 FR2404639B1 (en) 1985-06-14

Family

ID=27158695

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7729574A Expired FR2404639B1 (en) 1977-09-30 1977-09-30 NEW INDOLIC COMPOUNDS

Country Status (2)

Country Link
BE (1) BE884145R (en)
FR (1) FR2404639B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU84664A1 (en) * 1983-02-25 1984-11-08 Onmichem S A ALKYL-4-INDOLONAPHTYRIDINES AND THEIR THERAPEUTIC APPLICATION

Also Published As

Publication number Publication date
BE884145R (en) 1981-01-05
FR2404639B1 (en) 1985-06-14

Similar Documents

Publication Publication Date Title
ES2086270T3 (en) METABOLITES OF TERFENADINE AND ITS OPTICALLY PURE ISOMERS TO TREAT ALLERGIC DISORDERS.
US4839159A (en) Topical L-carnitine composition
ATE133336T1 (en) USE OF RAPAMYCIN IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EYE INFLAMMATION
BR9913153A (en) Normalization of substrate activity
ES511986A0 (en) "A PROCEDURE FOR THE PREPARATION OF NEW 1,2,3,4 TETRAHYDRO 2 NAFTILAMINAS".
DE3177092D1 (en) Medicinal composition for treatment of allergic diseases
Ramsay et al. The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis
FR2404639A1 (en) Chano-des:ethyl-apovincamine derivs.
DE59206403D1 (en) Use of xanthine derivatives for the manufacture of a medicament for the treatment of secondary nerve cell damage and functional disorders after traumatic brain injury
ES2145902T3 (en) APPLICATION OF RILUZOLE IN THE TREATMENT OF MITOCHONDRIAL DISEASES.
MX9603452A (en) Prostaglandin e, ester, liposome formulations containing them and medicine containing them.
LV10839A (en) Healing agent for prophylaxis of lipid and cholesterol metabolic disorders and treatment for this disorder prevention and treatment
KR880002527A (en) Eye composition for the treatment of neurodegeneration
ITRM920693A1 (en) USE OF L-CARNITINE AND ACIL L-CARNITINE IN THE TREATMENT OF PATIENTS WITH AIDS AND RELATED SYNDROMES AND ASYMPTOMATIC HIV-THERAPY PATIENTS.
KR970706271A (en) DRUGS TO IMPROVE SYNAPTIC TRANSMISSION
FR2698789B1 (en) Use of idazoxan and its derivatives for the preparation of a medicament intended for the treatment of Parkinson's disease and its evolution.
DE69627298D1 (en) USE OF SKLAREOLIDE FOR THE TREATMENT OF EXCESSIVE CELL GROWTH DISEASES
FR2428646A1 (en) 10-Bromo-vincamine derivs. - with anti-anoxia and psychotropic activity, used e.g. for treating cerebrovascular disorders
FR2434165A1 (en) 3a-Methyl-hexa:hydro-6-oxo-6H-indolo-(3,2,1-de) (1,5)-naphthyridine - of 3A-methyl-6-canthinone and 3-alkyl derivs. to treat depressive states, cardiovascular troubles and cerebral oxygenation insufficiency
US4128661A (en) (Bis-diethylamine)2,5-dihydroxybenzene-1,4-disulfonate, useful as a medicament against glaucoma
Sherif Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices
FR2428644A2 (en) 10-Bromo-vincamine derivs. - with anti-anoxia and psychotropic activity, used e.g. for treating cerebrovascular disorders
ES2058315T3 (en) EFFECTIVE COMPOUNDS AGAINST BRAIN FAILURE.
RU96105023A (en) AGENT FOR TREATMENT OF NEURAL DISEASES
FR2414507A1 (en) Trans or 21-epi-eburnamonine - for treatment of cerebral oxygenation insufficiency has superior therapeutic index to vincamine and vincamone

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name